PPARγ: An essential role in metabolic control

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 11, Issue 1, 2001, Pages 64-69

  Fajas, L ^a,b   Debril, M B ^a   Auwerx, J ^a  

^a CNRS   (France)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Adipogenesis; Insulin resistance; Nuclear receptor; Obesity; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; 9-DEOXY-DELTA-9-PROSTAGLANDIN D2; CELL RECEPTOR; DRUG DERIVATIVE; INSULIN; LIGAND; PROSTAGLANDIN D2; PROSTAGLANDIN J2; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR;

ADIPOSE TISSUE; ANIMAL; ARTERIOSCLEROSIS; GENE EXPRESSION; GENETICS; HUMAN; INFLAMMATION; METABOLISM; PHYSIOLOGY; REVIEW;

ADIPOSE TISSUE; ANIMALS; ARTERIOSCLEROSIS; GENE EXPRESSION; HUMANS; INFLAMMATION; INSULIN; LIGANDS; PROSTAGLANDIN D2; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0035260057     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark E, Chambon P, Evans RM (1995) The nuclear receptor superfamily: the second decade. Cell 83: 835-839
2. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A., Flier J., Briggs MR, Staels B, Vidal H., Auwerx J (1997) Organization, promoter analysis and expression of the human PPARg gene. J Biol Chem 272: 18779-18789
3. Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, Hsieh, L., Greene G., Nimer SD (1995) Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expression 4: 281-299
4. Beamer BA, Negri C, Yen CJ, Gavrilova O, Rumberger JM, Durcan MJ, Yarnall DP, Hawkins AL, Griffin CA, Burns DK, Roth J, Reitman M, Shuldiner AR (1997) Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene. Biochem Biophys Res Commun 233: 756-759
5. Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Rao MS., Reddy JK (1995) Structural organization of mouse peroxisome proliferator activated receptor g (mPPARg) gene: alternative promoter use and different splicing yield two mPPARg isoforms. Proc Natl Acad Sci USA 92: 7921-7925
6. Fajas L, Fruchart JC, Auwerx J (1998) PPARγ3 mRNA: a distinct PPARg mRNA subtype transcribed from an independent promoter. FEBS Lett 438: 55-60
7. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Laville M, Staels B, Auwerx J, Vidal H (1997) Tissue distribution and quantification of the expression of PPARs and LXRα in humans: no alterations in adipose tissue of obese and NIDDM patients. Diabetes 48: 1319-1327
8. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib, Witztum JL, Auwerx J, Palinski W, Glass C K (1998) Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95: 7614-7619
9. Kruszynska YT, Mukherjee R, Jow L, Dana S, Paterniti JR, Olefsky JM (1998) Skeletal muscle peroxisome proliferator-activated receptor-γ expression in obesity and non-insulin-dependent diabetes mellitus. J Clin Invest 101: 543-548
10. Park KS, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Nikoulina SE, Henry RR (1997) PPAR-gamma gene expression is elevated in skeletal muscle of obese and type II diabetic subjects. Diabetes 46: 1230-1234
11. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, Flier JS (1997) Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99: 2416-2422
12. Park KS, Ciaraldi TP, Lindgren K, Abrams-Carter L, Mudaliar S, Nikoulina SE, Tufari SE, Veerkamp JH, Vidal-Puig A, Henry RR (1998) Troglitazone effects on muscle gene expression in human skeletal muscle of Type II diabetes involve up-regulation of peroxisome proliferator-activated receptor γ. J Clin Endocrinol Metab 83: 2830-2835
13. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehman JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83: 813-819
14. Forman BM, Tontonoz P., Chen J., Brun RP., Spiegelman BM, Evans RM (1995) 15-Deoxy-D12,14 prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83: 803-812
15. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for Peroxisome Proliferator-Activated Receptor γ (PPARγ). J Biol Chem 270: 12953-12956
16. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA (1997) Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272: 3406-3410
17. Nolte R, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson T M, Glass CK, Milburn MV (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor γ. Nature 395: 137-143
18. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, Shiraisha I (1991) Effect of a new oral antidiabetic agent CS-045 in NIDDM subjects. Diabetes Care 14: 1083-1086
19. Schwartz S, Raskin P, Fonseca V, Graveline JF (1998) Effect of troglitazone in insulin-treated patients with type II diabetes. N Engl J Med 338: 861-866
20. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J (1994) Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331: 1188-1193
21. Suter SL, Nolan JJ, Wallace, Gumbiner B, Olefsky JM (1992) Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15: 193-203
22. Balfour JA., Plosker GL (1999) Rosiglitazone. Drugs 57, 921-930; discussion 931-922
23. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman B, Mortensen RM (1999) PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4: 611-617
24. Tontonoz P, Hu E, Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79: 1147-1156
25. Hu E, Tontonoz P, Spiegelman BM (1995) Transdifferentiation of myoblasts by the adipogenic transcription factors PPARγ and C/EBPa. Proc Natl Acad Sci USA 92: 9856-9860
26. Barsh GS, Farooqi IS., O'Rahilly S (2000) Genetics of body-weight regulation. Nature 404: 644-651
27. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR (1998) Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 339: 953-959
28. Deeb S, Fajas L, Nemoto M, Laakso M, Fujimoto W, Auwerx J (1998) A Pro 12 Ala substitution in the human peroxisome proliferator-activated receptor gamma2 is associated with decreased receptor activity, improved insulin sensitivity, and lowered body mass index. Nature Genet 20: 284-287
29. Vigouroux C, Fajas L, Khallouf E, Meier M, Gyapay G, Auwerx J, Weissenbach J, Capeau J, Magre J (1998) Human peroxisome proliferator-activated receptor gamma 2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes 47, 490-492
30. Beamer BA, Yen CJ, Andersen RE, Muller D, Elahi D, Cheskin LJ, Andres R, Roth J, Shuldiner, AR (1998) Association of the Pro12Ala variant in peroxisome proliferator-activated receptor gamma2 gene with obesity in two Caucasian populations. Diabetes 47: 1806-1808
31. Yen CJ, Beamer BA., Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR. (1997) Molecular scanning of the human peroxisome proliferator activated receptor gamma gene in diabetic Caucasians: identification of a Pro12Ala PPARγ 2 missense mutation. Biochem Biophys Res Commun 241: 270-274
32. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C, Kadowaki T (2000) The Pro12Ala Polymorphism in PPARγ2 May Confer Resistance to Type 2 Diabetes. Biochem Biophys Res Commun 271: 212-216
33. Lee MK., Miles PD, Khoursheed M, Gao KM, Moossa AR, Olefsky JM (1994) Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 43: 1435-1439
34. Rieusset J, Auwerx J, Vidal H (1999) Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun 265: 265-271
35. Loviscach M, Rehman N, Carter L, Mudaliar S, Mohadeen P, Ciaraldi TP, Veerkamp JH, Henry RR (2000) Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabetologia 43, 304-311
36. Moller DE, Flier JS (1991) Insulin resistance-mechanisms, syndromes, and implications. N Engl J Med 325: 938-948
37. Shimomura I, Hammer RE, Richardson JA., Ikemoto S, Bashmakov YJLG, Brown MS (1998) Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: a model for congenital generalized lipodystrophy. Genes Dev. 12: 3182-3194
38. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, Feigenbaum L, Lee E, Aoyama T, Eckhaus M, Reitman ML, Vinson C (1998) Life without fat: a transgenic mouse. Genes Dev 12: 3168-3181
39. Burant CF, Sreenan S, Hirano K-I, Tai T-AC, Lohmiller J, Lukens J, Davidson NO, Ross S, Graves RA (1997) Troglitazone action is independent of adipose tissue. J Clin Invest 100, 2900-2908
40. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose tissue expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259: 87-91
41. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity induced insulin resistance. Science 271: 665-668
42. Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil GS, Spiegelman BM (1994) Altered gene expression for tumor necrosis factor-α and its receptor during drug and dietary modulation of insulin resistance. Endocrinology 134: 264-270
43. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101: 1354-1361
44. Randle PJ, Garland PB, Hales CN, Newsholme EA (1961) The glucose-fatty acid cycle: its role in insulin sensitivity and metabolic disturbances of diabetes mellitus. Lancet 1: 785-789
45. Martin G, Schoonjans K, Staels B, Auwerx J (1998) PPARg activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 137: 75-80
46. Oakes ND, Camilleri S, Furler SM, Chisholm DJ, Kraegen EW (1997) The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue availability in the rat. Metabolism 46: 935-942
47. Wu M, Ventre J, Moller DE, Doebber T (1997) Correction of elevated glucose and triglycerides in Zucker diabetic fatty rats by thiazolidinediones parallels increased I-glycogen synthase and lipoprotein lipase activity in muscle and fat. Diabetes 46 (Suppl. 1): 237A
48. Shimaya A, Kurosaki E, Shioduka K, Nakano R, Shibasaki M, Shikama H (1998) YM268 increases the glucose uptake, cell differentiation, and mRNA expression of glucose transporter in 3T3-L1 adipocytes. Horm Metab Res 30: 543-548
49. Ribon V, Johnson JH, Camp HS, Saltiel AR (1998) Thiazolidinediones and insulin resistance: peroxisome proliferator-activated receptor g activation stimulates expression of the CAP gene. Proc Natl Acad Sci USA 95: 14751-14756
50. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM (1998) PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93: 241-252
51. Nagy L, Tontonez P, Alvarez JG, Chen H, Evans RM (1998) Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93: 229-240
52. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J (1998) Macrophages in human atheroma contain PPARgamma: differentiation-dependent PPARγ expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am J Pathol 153: 17-23
53. Marx N, Schoenbeck U, Lazar MA, Libby P, Plutzky J (1998) Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83: 1097-1103
54. Jackson SM, Parhami F, Xi X-P, Berliner J, Hsueh WA, Law RE, Demer LL (1999) Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 19: 2094-2104
55. Pasceri V, Wu HD, Willerson JT, Yeh ET (2000) Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation 101: 235-238
56. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H (1998) Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83: 1818-1820
57. Jiang C, Ting AT, Seed B (1998) PPARg agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86
58. Su GC, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD (1999) A novel therapy for colitis utilizing PPARγ ligands to inhibit the epithelial inflammatory response. J Clin Invest 104: 383-389